injection

SINGLE SHOT VACCINE DEVELOPED BY CRITICAL PHARMACEUTICALS

Single Shot Vaccine Developed by Critical Pharmaceuticals 01/08/2007 03:35

Single Shot Vaccine Developed by Critical Pharmaceuticals

Critical Pharmaceuticals today announced the successful completion of proof of concept of two single shot vaccines developed using their NanoMix™ technology. Vaccination has had a greater impact on public health and the treatment of infectious diseases than any other healthcare intervention. However, many vaccines require multiple doses over many months in order to develop a robust and protective immune response which leads to compliance and cost implications, particularly affecting the developing world. The development of effective vaccines that could be effective after one injection is therefore highly desirable.

To achieve this, Critical Pharmaceuticals encapsulated two vaccines – diphtheria and tetanus – into biodegradable polymers using their NanoMix™ technology. The polymers, which are approved by regulatory agencies around the world, slowly release the vaccine making booster injections unnecessary. In a project funded by the BBSRC under the Small Business Research Initiative (SBRI) Critical Pharmaceuticals showed following a 6 month pre-clinical study that a single injection of their formulations were as effective as a standard vaccine injected twice – once at the start of the study and with a booster injection half way through.

Dr Andy Lewis, Head of Formulation Development at Critical Pharmaceuticals said, “This is a real breakthrough in the development of the next generation of vaccines. In the future we expect every vaccine will be formulated in this way, making booster injections a thing of the past. Not only will people not have to remember to go back to the doctors for their booster injections, but people in the developing world will benefit greatly and we hope this may go some way to eradicating diseases in areas with limited access to healthcare. The results could not have been better, and we hope that we can take this forward by collaborating with a vaccine manufacturer.”

CriticalMix Technology

CriticalMix rig

CriticalMix enables the manufacture of highly active sustained release depot products for bimonthly, monthly or less frequent injection.

Read more

CriticalSorb Technology

nasal device

CriticalSorb enables the non-invasive nasal delivery delivery of high-value biologic products and challenging small molecule drugs.

Read more

Dr Andy Lewis, Critical Pharmaceuticals
“This is a real breakthrough in the development of the next generation of vaccines. In the future we expect every vaccine will be formulated in this way, making booster injections a thing of the past. Not only will people not have to remember to go back to the doctors for their booster injections, but people in the developing world will benefit greatly and we hope this may go some way to eradicating diseases in areas with limited access to healthcare. The results could not have been better, and we hope that we can take this forward by collaborating with a vaccine manufacturer.”